{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:18:35Z","timestamp":1774725515682,"version":"3.50.1"},"reference-count":78,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS (Japan Society for the Promotion of Science)","award":["#JP22K08675"],"award-info":[{"award-number":["#JP22K08675"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>The field of natriuretic peptides (NPs) as an endocrine hormone has been developing since 1979. There are three peptides in humans: atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which bind to the guanylyl cyclase-A (GC-A) receptor (also called natriuretic peptide receptor-A (NPR-A)), and C-type natriuretic peptide (CNP), which binds to the GC-B receptor (also called the NPR-B) and then synthesizes intracellular cGMP. GC-A receptor stimulation has natriuretic, vasodilatory, cardiorenal protective and anti-renin\u2013angiotensin\u2013aldosterone system actions, and GC-B receptor stimulation can suppress myocardial fibrosis and can activate bone growth before epiphyseal plate closure. These physiological effects are useful as therapeutics for some disease states, such as heart failure, hypertension, and dwarfism. To optimize the therapeutics for each disease state, we must consider drug metabolism, delivery systems, and target receptor(s). We review the cardiac NP system; new designer NPs, such as modified\/combined NPs and modified peptides that can bind to not only NP receptors but receptors for other systems; and oral drugs that enhance endogenous NP activity. Finally, we discuss prospective drug discoveries and the development of novel NP therapeutics.<\/jats:p>","DOI":"10.3390\/biology11060859","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T09:42:32Z","timestamp":1654335752000},"page":"859","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States"],"prefix":"10.3390","volume":"11","author":[{"given":"Tomoko","family":"Ichiki","sequence":"first","affiliation":[{"name":"Department of General Medicine, Sapporo Medical University, S1 W17, Sapporo 060-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-7343","authenticated-orcid":false,"given":"Atsushi","family":"Jinno","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Sapporo Medical University, S1 W17, Sapporo 060-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Sapporo Medical University, S1 W17, Sapporo 060-8556, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3181\/00379727-161-40584","article-title":"Heart atria granularity effects of changes in water-electrolyte balance","volume":"161","year":"1979","journal-title":"Proc. Soc. Exp. Biol Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3181\/00379727-170-41408","article-title":"Atrial natriuretic factor of the rat heart. Studies on isolation and properties","volume":"170","year":"1982","journal-title":"Proc. Soc. Exp. Biol. Medicine. Soc. Exp. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0006-291X(84)91077-5","article-title":"Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP)","volume":"118","author":"Kangawa","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0006-291X(90)92401-K","article-title":"C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain","volume":"168","author":"Sudoh","year":"1990","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2011","journal-title":"FEBS J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1507\/endocrj.K10E-164","article-title":"Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias","volume":"57","author":"Yasoda","year":"2010","journal-title":"Endocr. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jjcc.2010.08.001","article-title":"Roles of atrial natriuretic peptide and its therapeutic use","volume":"56","author":"Saito","year":"2010","journal-title":"J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-407680-8.00001-4","article-title":"BNP molecular forms and processing by the cardiac serine protease corin","volume":"61","author":"Ichiki","year":"2013","journal-title":"Adv. Clin. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1253\/circj.CJ-17-0499","article-title":"Atrial Natriuretic Peptide- Old But New Therapeutic in Cardiovascular Diseases","volume":"81","author":"Ichiki","year":"2017","journal-title":"Circ. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity","volume":"58","author":"Miyashita","year":"2009","journal-title":"Diabetes"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41598-018-19619-0","article-title":"Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes","volume":"8","author":"Coue","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109967","DOI":"10.1016\/j.cellsig.2021.109967","article-title":"Adrenal angiotensin II type 1 receptor biased signaling: The case for \u201cbiased\u201d inverse agonism for effective aldosterone suppression","volume":"82","author":"Ferraino","year":"2021","journal-title":"Cell Signal."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Guitart-Mampel, M., Urquiza, P., Borges, J.I., Lymperopoulos, A., and Solesio, M.E.E. (2021). Impact of Aldosterone on the Failing Myocardium: Insights from Mitochondria and Adrenergic Receptors Signaling and Function. Cells, 10.","DOI":"10.3390\/cells10061552"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications","volume":"227","author":"Kuwahara","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10641963.2014.987391","article-title":"Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide","volume":"37","author":"Miura","year":"2015","journal-title":"Clin. Exp. Hypertens"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Moyes, A.J., and Hobbs, A.J. (2019). C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092281"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1152\/physrev.00022.2015","article-title":"Molecular Physiology of Membrane Guanylyl Cyclase Receptors","volume":"96","author":"Kuhn","year":"2016","journal-title":"Physiol Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00210-019-01779-z","article-title":"cGMP: A unique 2nd messenger molecule\u2014Recent developments in cGMP research and development","volume":"393","author":"Friebe","year":"2020","journal-title":"Naunyn Schmiedebergs Arch. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Publication Committee for the VMAC Investigators (2002). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA, 287, 1531\u20131540.","DOI":"10.1001\/jama.287.12.1531"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0735-1097(01)01233-5","article-title":"Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction","volume":"37","author":"Hayashi","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","first-page":"151","article-title":"Nesiritide in acute decompensated heart failure: Current status and future perspectives","volume":"9","author":"Mohammed","year":"2008","journal-title":"Rev. Cardiovasc Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1253\/circj.CJ-07-0760","article-title":"Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study","volume":"72","author":"Nomura","year":"2008","journal-title":"Circ. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1253\/circj.CJ-08-0130","article-title":"Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: The PROTECT multicenter randomized controlled study","volume":"72","author":"Hata","year":"2008","journal-title":"Circ. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"Starling","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e005440","DOI":"10.1161\/CIRCHEARTFAILURE.118.005440","article-title":"Nesiritide and Me","volume":"11","author":"Kittleson","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1016\/S0021-9258(19)49658-0","article-title":"A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps)","volume":"267","author":"Schweitz","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","article-title":"Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP","volume":"52","author":"Lisy","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Martin, F.L., Sangaralingham, S.J., Huntley, B.K., McKie, P.M., Ichiki, T., Chen, H.H., Korinek, J., Harders, G.E., and Burnett, J.C. (2012). CD-NP: A novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0052422"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2014.08.001","article-title":"Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications","volume":"75","author":"Ichiki","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/0091270009336233","article-title":"Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects","volume":"49","author":"Lee","year":"2009","journal-title":"J. Clin. Pharm."},{"key":"ref_34","first-page":"546","article-title":"A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure","volume":"104","author":"Kawakami","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/eurheartj\/ehy566.P6528","article-title":"Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: A novel and safe therapeutic for humans with LVAD support","volume":"39","author":"Ichiki","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0735-1097(20)31415-7","article-title":"Cenderitide: A Novel Therapeutic to Increase Endogenous Cardiac Natriuretic Peptides in Heart Failure","volume":"75","author":"Ichiki","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.mayocp.2012.02.003","article-title":"Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension","volume":"87","author":"Cataliotti","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jacc.2012.05.049","article-title":"Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP","volume":"60","author":"Macheret","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00005344-198707000-00010","article-title":"Plasma immunoreactive atrial natriuretic peptide levels after subcutaneous alpha-hANP injection in normal humans","volume":"10","author":"Crozier","year":"1987","journal-title":"J. Cardiovasc. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMoa0706300","article-title":"Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation","volume":"359","author":"Karst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jacc.2009.04.080","article-title":"A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions","volume":"54","author":"McKie","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"R669","DOI":"10.1152\/ajpregu.00354.2019","article-title":"Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP","volume":"318","author":"Chen","year":"2020","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/HYPERTENSIONAHA.121.18837","article-title":"MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension","volume":"79","author":"Dzhoyashvili","year":"2022","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19196","DOI":"10.1074\/jbc.M109.010777","article-title":"A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation","volume":"284","author":"Dickey","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/HYPERTENSIONAHA.110.159210","article-title":"A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension","volume":"56","author":"McKie","year":"2010","journal-title":"Hypertension"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/HYPERTENSIONAHA.121.17159","article-title":"First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.0811851106","article-title":"Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide","volume":"106","author":"Pan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jacbts.2016.10.001","article-title":"Innovative Therapeutics: Designer Natriuretic Peptides","volume":"1","author":"Meems","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"R407","DOI":"10.1152\/ajpregu.00286.2017","article-title":"CRRL269: A novel designer and renal-enhancing pGC-A peptide activator","volume":"314","author":"Chen","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1161\/CIRCRESAHA.118.314164","article-title":"Crrl269","volume":"124","author":"Chen","year":"2019","journal-title":"Circ. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/371252a0","article-title":"Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia","volume":"371","author":"Rousseau","year":"1994","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3-Related Dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: A randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias","volume":"370","author":"Breinholt","year":"2019","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/HYPERTENSIONAHA.118.12012","article-title":"Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide","volume":"73","author":"Meems","year":"2019","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.1002941107","article-title":"Ghrelin and growth hormone: Story in reverse","volume":"107","author":"Nass","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Morozumi, N., Yotsumoto, T., Yamaki, A., Yoshikiyo, K., Yoshida, S., Nakamura, R., Jindo, T., Furuya, M., Maeda, H., and Minamitake, Y. (2019). ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212680"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Yotsumoto, T., Morozumi, N., Nakamura, R., Jindo, T., Furuya, M., Abe, Y., Nishimura, T., Maeda, H., Ogasawara, H., and Minamitake, Y. (2019). Safety assessment of a novel C-type natriuretic peptide derivative and the mechanism of bone- and cartilage-specific toxicity. PLoS ONE, 14.","DOI":"10.1101\/655548"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/CIRCULATIONAHA.105.538520","article-title":"Oral human brain natriuretic peptide activates cyclic guanosine 3\u2019,5\u2019-monophosphate and decreases mean arterial pressure","volume":"112","author":"Cataliotti","year":"2005","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: A randomised, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","article-title":"Atrial Natriuretic Peptide and Treatment With Sacubitril\/Valsartan in Heart Failure With Reduced Ejection Fraction","volume":"9","author":"Murphy","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bmc.2017.01.026","article-title":"Discovery and dimeric approach of novel Natriuretic Peptide Receptor A (NPR-A) agonists","volume":"25","author":"Iwaki","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1016\/j.bmcl.2017.09.028","article-title":"Discovery and SAR of a novel series of Natriuretic Peptide Receptor-A (NPR-A) agonists","volume":"27","author":"Iwaki","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1016\/j.bmc.2017.11.006","article-title":"Discovery and in vivo effects of novel human natriuretic peptide receptor A (NPR-A) agonists with improved activity for rat NPR-A","volume":"25","author":"Iwaki","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e2109386118","DOI":"10.1073\/pnas.2109386118","article-title":"Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators","volume":"118","author":"Sangaralingham","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2011.01.005","article-title":"Pro-B-type natriuretic peptide(1-108) circulates in the general community: Plasma determinants and detection of left ventricular dysfunction","volume":"57","author":"Macheret","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","article-title":"Circulating aldosterone and natriuretic peptides in the general community: Relationship to cardiorenal and metabolic disease","volume":"65","author":"Buglioni","year":"2015","journal-title":"Hypertension"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.111.00791","article-title":"Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men","volume":"62","author":"Asferg","year":"2013","journal-title":"Hypertension"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jchf.2019.05.012","article-title":"Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP","volume":"7","author":"Reginauld","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jchf.2020.10.008","article-title":"Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure","volume":"9","author":"Bachmann","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/6\/859\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:23Z","timestamp":1760138663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/6\/859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["biology11060859"],"URL":"https:\/\/doi.org\/10.3390\/biology11060859","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]}}}